Abstract
IntroductionmicroRNAs are a family of small non protein-coding RNAs. They are involved in post-transcriptional gene regulation of their target genes. The deregulation of microRNAs has been linked to cancer development and tumor progression. The aim of out study was to look for microRNA-141 as a diagnostic and prognostic biomarker for prostate cancer. Patients and methodsThe study prospectively recruited 30 patients newly diagnosed with prostate cancer; including 13 and 17 patients without and with metastases, respectively. Another 30 patients without prostate cancer diagnosis were included as a control group. Real-time polymerase chain reaction analysis was done for relative quantification of microRNA-141. ResultsThe present study showed that microRNA-141 was significantly upregulated in cancerous patients compared to control group. Also it was significantly upregulated in patients with metastatic disease compared to non-metastatic patients. Moreover, it was significantly correlating with serum PSA and Gleason score. ConclusionSerum microRNA-141 could be a promising diagnostic and prognostic biomarker for prostate cancer and a good indicative of disease aggressiveness.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
